IL6 and rheumatoid arthritis: This will involve testing their ability to inhibit the production and activity of their respective targets (TNF-α and IL-6) in relevant cellular models of RA, such as cytokine-stimulated human fibroblast-like synoviocytes (HFLS) or peripheral blood mononuclear cells (PBMCs).